Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Naïve B-cell receptors (BCRs) specific for diphtheria, tetanus, pertussis, poliovirus, and Hib PRP epitopes are membrane-bound immunoglobulins on B lymphocytes that recognize specific pathogen-derived antigens (Janeway et al., Immunobiology, 2001). These receptors are the primary targets for multi-component vaccines such as DTaP-IPV-Hib, which aim to induce protective immunity against Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, Poliovirus, and Haemophilus influenzae type b (CDC, Pink Book, 2021). Upon antigen binding, these BCRs initiate signal transduction through the Ig-alpha and Ig-beta complex, leading to B-cell activation and differentiation into plasma cells and memory B cells (Reth & Wienands, Annual Review of Immunology, 1997). The Hib component specifically targets BCRs recognizing the polyribosylribitol phosphate (PRP) capsular polysaccharide, often conjugated to a protein carrier to enhance T-cell dependent responses (Frasch, Vaccine, 1995). This collective target is central to pediatric immunization strategies, ensuring the development of long-term humoral immunity against multiple life-threatening diseases.
Vaccine antigens bind to the variable regions of specific naïve B-cell receptors, inducing receptor clustering and activation of intracellular signaling cascades (e.g., Lyn, Syk, and PLC-gamma2). This leads to antigen internalization, processing, and presentation to T-helper cells, resulting in B-cell proliferation, isotype switching, and affinity maturation within germinal centers (Murphy & Weaver, Janeway's Immunobiology, 2016).
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Naïve B-cell receptors specific for diphtheria, tetanus, pertussis, poliovirus, and Haemophilus influenzae type b epitopes (Naïve BCRs (DTP-IPV-Hib)).